On October 2, 2023, BGI Genomics signed a Memorandum of Understanding (MoU) with the Colombian National Cancer Institute (INC or Instituto Nacional de Cancerologia). This collaboration, which goals to foster research and further develop cutting-edge solutions based on genetic sequencing for early diagnosis of cervical and colorectal cancer, reflects a shared dedication to enhancing health outcomes within the region.

The MoU was formally inked at INC facilities by Dr. Carolina Wiesner, INC Director, and Mr. Rainer Perez, alternate legal representative of BGI Genomics in Colombia. Mr. Marco Antonio Rincón, Latin America Business Director, BGI Genomics, notes: “BGI Genomics is one hundred pc committed to providing cost-effective tools for the prevention and management of Human papillomavirus (HPV) and colorectal cancer to make a meaningful impact on the healthcare of Colombian people.” As a part of this MoU, BGI Genomics may even train INC personnel.

The Colombian National Cancer Institute was created in 1934, and for over seven many years the INC has been committed to the supply of a comprehensive approach to prevention, treatment, rehabilitation and research of cancer within the Colombian population. Earlier, on September 26, 2023, Mr. Rincón took part as a panelist on behalf of BGI Genomics on the Health and Innovation Event throughout the eighth China-Colombia Dialogue Conference, held in Bogota, Colombia.

This event, organized by the Colombian Chinese Chamber of Investment & Commerce and the Embassy of the People’s Republic of China in Colombia, provided a platform for thought leaders to debate critical healthcare issues. Dr. Carolina Gómez, Manager of Bogotá Bio and Colombian Health Ministry Advisor, moderated a panel where Mr. Rincón emphasized BGI Genomics’ commitment to strengthening local human skills and talent with every local project. He also emphasized that the corporate seeks to advertise access to modern, precision and cost-effective technologies for the country’s health system.